Home - VHIO

Leading experts update on the role and relevance of consortia in the delivery of precision oncology early phase clinical trials

Co-authored by leading experts in oncology, a review article recently published in the Journal of Clinical Oncology (JCO)* provides an...

Dr. Josep Tabernero en el laboratorio con bata blanca VHIO

VHIO’s Director Josep Tabernero elected to the 2025 class of Fellows of the American Association for Cancer Research Academy

The American Association for Cancer Research (AACR) has officially announced this year’s class of Fellows of the AACR Academy. The...

Radioligand therapy demonstrates improved clinical benefit in patients with gastroenteropancreatic neuroendocrine tumors vs. molecular targeted therapy

Initial results of the COMPETE phase 3 clinical trial⁠—the first study to compare targeted radioligand therapy with molecular targeted therapy...

Co-authored by leading experts in oncology, a review article recently published in the Journal of Clinical Oncology (JCO)* provides an...

Leading experts update on the role and relevance of consortia in the delivery of precision oncology early phase clinical trials

The American Association for Cancer Research (AACR) has officially announced this year’s class of Fellows of the AACR Academy. The...

VHIO’s Director Josep Tabernero elected to the 2025 class of Fellows of the American Association for Cancer Research Academy

Initial results of the COMPETE phase 3 clinical trial⁠—the first study to compare targeted radioligand therapy with molecular targeted therapy...

Radioligand therapy demonstrates improved clinical benefit in patients with gastroenteropancreatic neuroendocrine tumors vs. molecular targeted therapy

Latest News

Co-authored by leading experts in oncology, a review article recently published in the Journal of Clinical Oncology (JCO)* provides an...

18 March 2025

Leading experts update on the role and relevance of consortia in the delivery of precision oncology early phase clinical trials

Co-authored by leading experts in oncology, a review article recently published in the Journal of Clinical Oncology (JCO)* provides an...

The American Association for Cancer Research (AACR) has officially announced this year’s class of Fellows of the AACR Academy. The...

10 March 2025

VHIO’s Director Josep Tabernero elected to the 2025 class of Fellows of the American Association for Cancer Research Academy

The American Association for Cancer Research (AACR) has officially announced this year’s class of Fellows of the AACR Academy. The...

Initial results of the COMPETE phase 3 clinical trial⁠—the first study to compare targeted radioligand therapy with molecular targeted therapy...

06 March 2025

Radioligand therapy demonstrates improved clinical benefit in patients with gastroenteropancreatic neuroendocrine tumors vs. molecular targeted therapy

Initial results of the COMPETE phase 3 clinical trial⁠—the first study to compare targeted radioligand therapy with molecular targeted therapy...

On February 26, the second edition of the Computational Oncology Master Thesis Awards took place, organized by VHIO with the aim of...

27 February 2025

VHIO presents the 2nd edition of the Computational Oncology Master Thesis Awards

On February 26, the second edition of the Computational Oncology Master Thesis Awards took place, organized by VHIO with the aim of...

VIEW MORE NEWS

PRINCIPAL RESEARCHERS

Cristina Saura

Breast Cancer & Melanoma Group

The main area of expertise of the Breast Cancer Group is clinical research focused on drug development and associated translational…

Elena Garralda

Early Clinical Drug Development Group

We focus on proof-of-concept and proof-of-mechanism trials with targeted therapies, with particular emphasis on cell signaling, cancer stem cells, and…

Teresa Macarulla

Gastrointestinal and Endocrine Tumors Group

Our group continues to play an essential role in developing molecular therapies against GI malignancies. We make important contributions to…

Alena Gros

Tumor Immunology and Immunotherapy Group

Our group focuses on better understanding the naturally occurring T-cell response to cancer and establishing ways to exploit these antitumor…

Events

Thursday 13 November 25 - 09:00 AM 2nd VHIO-BBVA Foundation Symposium on Cell-Based Therapies in Oncology

VIEW DETAIL